re: interisting trades/annoucement Recent studies carried out by Solbec Pharmaceuticals on its lead cancer drug SBP002 have lead the company to believe that the drug plays three very important roles in the treatment of cancer.
It is know that SBP002 will target cancerous tumours resulting in aggressive tumour death. The way in which SBP002 destroys tumour is unique and it is this unique mode of action that has highlighted that SBP002 may also activate the immune system to destroy both the primary tumour and any micro metastases (secondary tumours) even after the drug has left the system.
This is an important observation stated Solbec’s Managing Director, Stephen Carter, whilst it is still too early to be absolutely sure that SBP002 does activate the immune system to attack cancerous tissue, there is evidence that this may be what we have been seeing in some of our Special Access Scheme patients.
Solbec are discussing with researchers as to the best way to confirm these observations. If Solbec can confirm that SBP002 does activate the immune system as well as target the tumours direct, the drug potential will increase enormously.
The benefits of chemotherapy can be assessed by tumour size reduction, prolongation of life or simply by palliation of symptoms. Many of the patients treated with SBP002 reported an increase in their well being, improved appetite and even reduced use of their pain killers. To investigate what could be happening, Solbec commissioned the University of Western Australia’s, University Department of Medicine to investigate the effect of SBP002 on a chemical called Interlukin 6 (IL-6). IL-6 has been shown to effect the well being of animals with advanced disease. It is known to be a promoter of cachexia, a condition of wasting and emaciation in people with advanced disease. SBP002 was also compared against two of the current chemotherapies Gemcitabine and Docetexol.
The results were exciting with SBP002 inhibiting the production of IL-6, whilst the other compounds promoted the production of IL-6 by the cells. This may explain why up to 60% of the patients treated with SBP002 report an increased feeling of well being with reduction in pain, reduced use of narcotic pain killers and improved appetite.
It is possible that SBP002 could also act as a palliative care product in advanced cancer patients.
Solbec are currently working with key researchers to further define the role SBP002 will play in the treatment of cancer. We are excited by the standard of results achieved to-date and hope to be able to provide more clinical data to the market in the future.
STEPHEN CARTER
have a good day
SBP
solbec pharmaceuticals limited
